| 主权项 |
1. A prosthetic atrioventricular valve, comprising:
a biodegradable and remodelable continuous tubular member having proximal and distal ends, and a lumen therethrough, said continuous tubular member lumen defining a tubular member internal surface, said tubular member comprising a first extracellular matrix (ECM) composition comprising a first ECM material and a HMG-CoA reductase inhibitor selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin; and a biodegradable and remodelable reinforcement member comprising at least two elongated linear cardiovascular structure engagement members, said reinforcement member further comprising a second ECM composition comprising a second ECM material and an additional biologically active agent, said biologically active agent comprising a growth factor selected from the group consisting of transforming growth factor alpha (TGF-alpha), transforming growth factor beta (TGF-beta), fibroblast growth factor-2 (FGF-2), basic fibroblast growth factor (bFGF) and vascular epithelial growth factor (VEGF), said reinforcement member being disposed in said continuous tubular member lumen and attached to said distal end of said continuous tubular member, wherein said at least two elongated linear cardiovascular structure engagement members project outwardly from said continuous tubular member lumen, said reinforcement member being configured to connect said at least two elongated linear cardiovascular structure engagement members to a cardiovascular structure when said reinforcement member is attached to said continuous tubular member, wherein said prosthetic atrioventricular valve induces host tissue proliferation, bioremodeling and regeneration of new cardiovascular tissue with site-specific structural and functional properties. |
